James Greenwood is named as a lobbyist on federal disclosure filings for 12 clients through Dla Piper LLP (us). The most recent filing naming them posted in August 2025. Issues reported include Health Issues, Pharmacy, Government Issues and Medical/Disease Research/Clinical Labs.
Filers must list covered executive or legislative branch positions held. As filed:
| Client | Registrant | Latest | Issues |
|---|---|---|---|
| BIOHAVEN PHARMACEUTICALS, INC. | DLA PIPER LLP (US) | Q4 2022 | Health Issues |
| IQVIA HOLDINGS, INC. | DLA PIPER LLP (US) | Q2 2024 | Health Issues |
| INTRA-CELLULAR THERAPIES, INC. | DLA PIPER LLP (US) | Q1 2024 | Health Issues |
| CURRAX PHARMACEUTICALS LLC | DLA PIPER LLP (US) | Q1 2024 | Pharmacy |
| IMMUNOCORE, LLC | DLA PIPER LLP (US) | Q3 2023 | Health Issues |
| ILLUMINA, INC. | DLA PIPER LLP (US) | Q2 2023 | Government Issues |
| AMERIHEALTH CARITAS | DLA PIPER LLP (US) | Q2 2023 | Medicare/Medicaid, Medical/Disease Research/Clinical Labs |
| GENENTECH USA, INC. | DLA PIPER LLP (US) | Q4 2022 | Health Issues |
| SAB BIOTHERAPEUTICS, INC. | DLA PIPER LLP (US) | Q4 2022 | Pharmacy |
| ST. GEORGES UNIVERSITY | DLA PIPER LLP (US) | Q4 2021 | Education |
| GLOBAL PLASMA SOLUTIONS INC. | DLA PIPER LLP (US) | Q3 2021 | Environment/Superfund |
| FLIPT, LLC | DLA PIPER LLP (US) | Q3 2021 | Pharmacy |
| Year | Clients | Registrants |
|---|---|---|
| 2024 | 4 | 1 |
| 2023 | 7 | 1 |
| 2022 | 8 | 1 |
| 2021 | 7 | 1 |
| Year | Items | Total |
|---|---|---|
| 2023 | 3 | $8K |
| 2022 | 2 | $2K |
Pay is not disclosed for individual lobbyists. Filings do not confirm that records with the same name are one person, so this page may combine people who share the name James Greenwood. See the Capitol Clarity rankings and method.